BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671

Reuters12-17 22:38

BRIEF-Structure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671

Dec 17 (Reuters) - Structure Therapeutics Inc GPCR.O:

STRUCTURE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY OF ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 FOR THE TREATMENT OF OBESITY

Source text: ID:nGNX7vjtC7

Further company coverage: GPCR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592150739?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592150739","market":"nz","top_or_hot":-1,"title":"BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Structure Therapeutics Inc <span>GPCR.O</span>:</p><ul><li><p>STRUCTURE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY OF ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 FOR THE TREATMENT OF OBESITY</p></li></ul><p>Source text: <span>ID:nGNX7vjtC7</span></p><p>Further company coverage: <span>GPCR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Structure Therapeutics Inc <span>GPCR.O</span>:</p><ul><li><p>STRUCTURE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY OF ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 FOR THE TREATMENT OF OBESITY</p></li></ul><p>Source text: <span>ID:nGNX7vjtC7</span></p><p>Further company coverage: <span>GPCR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GPCR","symbol_name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5Z08HX:1","article_id":"2592150739","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592150739","pubTimestamp":1765982287,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG2671Dec 17 (Reuters) - Structure Therapeutics Inc GPCR.O:STRUCTURE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL ST","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4599":"减肥药","BK4007":"制药"},"translate_title":"BRIEF-Structure Therapeutics开始口服胰淀素激动剂ACCG-2671的1期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPCR":0.9},"content_text":"BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671Dec 17 (Reuters) - Structure Therapeutics Inc GPCR.O:STRUCTURE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY OF ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 FOR THE TREATMENT OF OBESITYSource text: ID:nGNX7vjtC7Further company coverage: GPCR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592150739","isCrawlerRequest":true}